Flow cytometry is a widely used technique for single-cell and particle analysis. For flow cytometry to be used in a clinical, industrial, or research setting, measurements must be made precisely and with sufficient measurement assurance. Our objective is to develop reference materials, methodology and procedures to enable quantitative measurements of biological substances such as cells, extracellular vesicles, proteins, and nucleic acids. By providing quantitative flow cytometry measurement solutions, we ensure that researchers and clinicians can produce more reliable data, develop better drugs, and provide better treatment to patients in the clinical setting.
Flow cytometry is an essential tool for basic immunological research, the clinical discovery of potential therapeutics, development, and approval of drugs and devices, disease diagnosis, and therapeutic treatment and monitoring. For example, flow cytometry is commonly used in pre-clinical and clinical trials for evaluating the safety/efficacy of drugs including engineered T-cells. In HIV/AIDS monitoring, accurate measurement of CD4+ cell counts using flow cytometry is the key to ensuring that patients receive the appropriate antiretroviral treatment (ART). However, the measurements made on different instrument platforms at different times and places often cannot be compared. Discrepancies between and among measurements introduce uncertainty in diagnostic and therapeutic decisions and impede advances in basic science. We collaborate with other government agencies, industry, academia, professional societies, standards organizations, and field experts to accelerate the standardization of flow cytometry measurements with the use of reference controls and standards and measurement procedures.
1. Flow Cytometry Quantitation Consortium – The objective of the consortium is to collaboratively develop reference standards including biological reference materials, reference data, reference methods, and service for assigning the equivalent number of reference fluorophores (ERF) to calibration microspheres and assessing the associated uncertainties and utilities. This is the first step towards reliable quantitative measurements in flow cytometry.
To learn more about the Flow Cytometry Quantitation Consortium, click here.
2. Quantification of Cells with Specific Phenotypic Characteristics – A Broad International Collaborative Effort for the Development of Human Blood Cell-based Reference Materials and Controls
(I) Accurate enumeration of cells with specific phenotypic characteristics is of critical importance in inpatient care. There are pertinent needs for cell reference materials for external measurement quality assessments in areas, such as HIV/AIDS monitoring (CD4+ cell count) and blood transfusion (CD45+CD34+ stem cell count) in clinics. Our scientists have produced and evaluated the first international reference standard for CD4+ cell counting for HIV/AIDS monitoring (WHO BS/10.2153). Accurate measurement of CD4+ cells is the key to ensuring that patients receive the appropriate anti-retroviral treatment (ART) once their CD4+ cell count falls below 350 cells per microliter.
(II) Due to the enormous potential and the recent success of immunotherapy in clinics, there are urgent needs for cell reference materials and standardized protocols to evaluate T cell functionalities. Intracellular cytokines are crucial indicators of immune function and competence. Our scientists have generated and evaluated a cellular reference material using a freeze-dried preparation of unstimulated (NIBSC code: SS570) peripheral blood mononuclear cells (PBMCs) and phorbol 12-myristate 13-acetate (PMA)/ionomycin stimulated PBMC (NIBSC code:15/272), obtained from healthy blood donors. A flow cytometric-based, the rapid single-step method has been developed and validated across different instrument platforms in three different laboratories for enumerating cytokine positive T lymphocytes.
3. Quantitative Measurements of Immuno-Oncology Markers and Disease Biomarkers – (I) PD-L1 (programmed cell death 1 ligand 1) expression has been identiﬁed as a predictive diagnostic marker to select patients that may beneﬁt from anti-PD-1 (programmed cell death 1) therapies such as nivolumab, pembrolizumab, atezolizumab, and durvalumab. Currently, there are multiple qualitative PD-L1 assays on the market, either FDA approved, or laboratory-developed tests, involving various antibodies, to assess the expression of PD-L1 by immunohistochemistry (IHC) using chromogenic methods. Due to the lack of result traceability and comparability using these clinical PD-L1 IHCs, we are working with the IHC community to use the quantification scheme established in flow cytometry and mass spectrometry to undertake the traceability and comparability issue in IHC. A calibrator system consists of a set of cell-sized glass microbeads covalently attached with fluorescein-conjugated recombinant PD-L1 protein and unlabeled peptide. Each glass microbead population is defined by a specific ratio of fluorescein-labeled recombinant PD-L1 protein and unlabeled peptide. The fluorescence intensity in the units of ERF of each microbead population is measured based on the NIST SRM 1934 under the Flow Cytometry Quantitation Consortium. Cultured cells of the human epidermal receptor protein-2 (HER2) breast cancer cell lines, e.g. MDA-MB-361, MDA-MB-453, and SK-BR-3 with different expression levels of PD-L1 that are quantified using quantitative mass spectrometry would enable the transformation of PD-L1 copy number to the calibration established by the microbead calibrators using flow cytometry. These bead calibrators serve as the calibration system for both flow cytometry and IHC. The translation of PD-L1 copy number per cell onto the glass bead calibration enables a quantitative and comparable measure of analyte PD-L1 in IHC.
(II)Flow cytometry has been critical for establishing identity, purity, and potency for cell therapy product manufacturing and associated data to support the approval of Biological License Applications by the U.S. FDA and the approval by the EMA. It is essential to establish B-cell reference control materials for comparable and quantitative cytometric expression analysis to assist cell therapy manufacturing and immunotherapy monitoring. Our scientists are quantifying the expression levels of CD19 on B cells in the instrument independent unit of antibodies bound per cell (ABC) as well as their respective associated uncertainties for three commercial lyophilized or dried-down PBMC preparations. The work is inspired by a consensus outcome from flow cytometry workshops that call for cell reference standards with well-characterized antigen expression and immunophenotyping profiles for advanced cell manufacturing and cell therapies. We envision that the PBMC-based materials in this study will be useful as expression analysis reference markers for quantifying disease and immunotherapy relevant B cell markers, e.g. CD19, CD20, and CD22. Quantitative measurement of these biomarkers of B-cell malignancies with high confidence is critically important for the determination of proper treatment options and regimens, e.g. switching drugs and applying a second dose of the same drug, and hence improving patient’s quality of life.
4. Development of Process Control Materials and Protocols for Reliable Extracellular Vesicle Measurements Using Flow Cytometry – Extracellular vesicles (EVs), which are biologically active lipid bilayer membranes, have been at the forefront of life science research due to their significant role in both physiological and pathological processes. Research on EV’s role in these processes has been primarily focused on exosomes (30–150 nm) or microvesicles (200–1,000 nm). In order to rapidly analyze these materials, flow cytometry has become one of the critical characterization tools due to its high-throughput and multi-parameter analysis capabilities. However, the analysis of EVs by flow cytometry has been limited, not only due to their small sizes and weak signals from fluorescent labels but also by the limited experience level of many instrument users owing to the lack of process control materials. Therefore, detailed procedures to fine-tune the flow cytometer through careful calibration and APD (or PMT) setting adjustment using known control materials have become key in obtaining reliable and meaningful data. We present an example of using a set of polystyrene nanoparticles (80-300 nm in size) to serve as references for the user to establish proper instrument settings prior to EV sample analysis. In addition, 100 nm FITC and PE like nanoparticle preparations are under evaluation for their suitability as reference control materials for fluorescence intensity calibration and EV counting. All measurements were carried out using a CytoFlex flow cytometer.
5. Proteomic and Genomic Analysis of CRISPR/Cas9 Engineered Cells and Cell Stability – A commonly used genome editing system, being used for improving protein, cell, and gene therapies is CRISPR/Cas9. While this tool has great potential, long-term data about its genomic and phenotypic stability and off-target effects that may arise during the editing process are sparse. Since the entire cell can be used in a patient with cell and gene therapies, cell characterization is essential for safety. In support of the production of safe and effective CRISPR/Cas9 engineered protein, cell and gene therapies, the objective of this work is to study both on-target and off-target effects of CRISPR/Cas9 using flow cytometry on a B-lymphoblast cell line, GM24385, whose genome sequence has been well characterized. Importantly, this project enables us to extend our flow cytometry capability to measure transcriptomes and proteomes of interest simultaneously at a single-cell level.
6. Rare Events Quantitation Using Quantum Cytometer – Cancer cell heterogeneity, long recognized as an important clinical determinant of patient outcomes, is poorly understood at a molecular level, mostly due to the current limitation of rare event quantitation at a single-cell level. PCR-based approaches require extracted DNA from patient samples, resulting in average values and losing information on the cellular and population heterogeneity. Other methods such as IHC and fluorescence in situ hybridization (FISH) produce qualitative or sub-quantitative results at best. The quantum cytometer has the potential to detect rare events in a single cell in a high-throughput and quantitative manner. We collaborate with Dr. Sergey Polyakov at the Physical Measurement Laboratory of NIST to use a breast cancer biomarker, HER2 (or called ERBB2), as a model to develop and validate the quantum cytometer for rare events measurement. The five breast cancer cell lines, that were used to produce NIST SRM 2373 with different amounts of HER2 gene amplification (from normal 2 copies per cell to middle ~5 and 8 copies/cell, and to 10 or more copies per cell) in our lab, will be used for testing rare events detection. The HER2 gene in a single cell will be hybridized to a quantum dot labeled HER2 gene probe and then be detected by the quantum cytometer via quantum statistics of observed photons. This method will be providing an absolute quantification through direct counting of the number of quantum dots per cell. This flow-FISH cytometric assay can be expanded in the future for simultaneous detection of rare event gene mutation and protein biomarkers at a single cell level for molecular and conventional pathology. Moreover, it will be applicable to other significant NIST programmatic areas in regenerative medicine, engineering biology, and precision medicine, e.g. vector copy number measurements and genomic editing on and off-target counts at a single-cell level.
NIST-NRC Postdoctoral Fellowship Opportunities: